Skip to Content

Emsam Approval History

  • FDA approved: Yes (First approved February 27th, 2006)
  • Brand name: Emsam
  • Generic name: selegiline
  • Dosage form: Transdermal System
  • Company: Somerset Pharmaceuticals, Inc.
  • Treatment for: Depression, Major Depressive Disorder

Emsam is a transdermal patch containing the monoamine oxidase inhibitor selegiline. Emsam is indicated for the treatment of major depressive disorder (MDD) in adults.

Development History and FDA Approval Process for Emsam

Feb 28, 2006Approval Emsam Approved - Bristol-Myers Squibb Company/Somerset Pharmaceuticals, Inc. - Treatment for Major Depressive Disorder
Jun 16, 2005Somerset Files Response to Emsam Action Letter
Feb  2, 2004Mylan Laboratories and Watson Pharmaceuticals Announce Receipt of "Approvable" Letter for Emsam

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.